RxDoctor Payments Data

Wael Saber, MD

Hematology & Oncology · Milwaukee, WINPI 1730145863

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,800 of the $10,497 with a category attached, or 93.4%. Pfizer accounts for 94.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $6,600 and has fallen 95.5% since, to $296 in 2024.

$10,497in general payments, 2019–2025

Across 8 payments — averaging $1312.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10K
  • National Marrow Donor Program$215
  • Beigene USA, Inc.$184
  • Bristol Myers Squibb$114
  • Sobi, Inc$81
$2,686,622in research payments, 2019–2025

Across 47 payments — averaging $57,162 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.2M
  • Amgen$771K
  • Swedish Orphan Biovitrum AB$699K

What the payments were for

  • Speaking & faculty fees$9,80093%
  • Food & beverage$6977%

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,497 in reported general payments places this provider in the 80th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$6,972
Medicare patients
28
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →